426
Participants
Start Date
May 31, 2003
Study Completion Date
September 30, 2006
rhuFab V2 (ranibizumab)
Ophthalmic Consultants of Long Island, Rockville Centre
Lions Eye Institute, Albany
Allegheny General Hospital, Pittsburgh
Pennsylvania Retina Specialists, Camp Hill
Wills Eye Hospital, Philadelphia
Retina Associates PC, Annapolis
Retina Group of Washington, Fairfax
Duke Univ Medical Center/Duke Eye Center, Durham
Southeast Clinical Research, Charlotte
Western Carolina Retinal Associates, PA, Asheville
Palmetto Retina Center, Columbia
Retina Consultants of Charleston, Charleston
Emory University, Atlanta
Medical College of Georgia, Augusta
Florida Retina Institute, Daytona Beach
Southern Vitreoretinal Associates PA, Tallahassee
Central Florida Retina, Orlando
Retina Associates of South Florida, Margate
Bascom Palmer Eye Institute, Miami
Retina Vitreous Consultants, Fort Lauderdale
Retina Care Specialists, Palm Beach Gardens
Bascom Palmer Eye Institute, Palm Beach Gardens
University of South Florida, Tampa
Retina Consultants of Southwest Florida, Fort Myers
Retina Health Center, Fort Myers
Ophthalmic Consultants, Sarasota
Retina Vitreous Associates, Nashville
Southeastern Retina Associates, P.C., Knoxville
Midwest Retina, Columbus
Retina Vitreous Associates, Toledo
Retina Associates of Cleveland, Beachwood
Cleveland Clinic Foundation/Cole Eye Institute, Cleveland
Flavio Company, Cincinnati
Thomas A. Ciulla, MD, PC, Indianapolis
Retina Consultants of Michigan, Southfield
Associated Retinal Consultants, P.C., Royal Oak
University of Michigan, Ann Arbor
Associated Retinal Consultants, Grand Rapids
Medical College of Wisconsin, Milwaukee
BH Regional Eye Institute, Rapid City
Retina Associates of St. Louis, Florissant
St. Louis University Eye Institute, St Louis
University of Kansas Medical Center, Kansas City
Retinal Associates of Oklahoma, Oklahoma City
Retina Specialists, DeSoto
Vitreoretinal Consultants, Houston
UTMB, Galveston
Univ of Texas Health Science Center, San Antonio
Medical Center Ophthalmology, San Antonio
Valley Retina Institute, P.A., McAllen
Austin Retina Associates, Austin
Brian Berger, MD P.A., Austin
Rocky Mountain Retina Consultants, Salt Lake City
John Moran Eye Center/Univ of Utah, Salt Lake City
Retina Centers, P.C., Tucson
University of Arizona, Tucson
Doheny Eye Institute, Los Angeles
Retina-Vitreous Associates Medical Group, Beverly Hills
UC Irvine, Irvine
California Vitreoretinal Research Center, Menlo Park
No. California Retina-Vitreous Associates, Mountain View
UCSF School of Medicine, San Francisco
Retina & Vitreous Center of So. Oregon, Ashland
Vitreoretinal Associates, Seattle
Danbury Eye Physicians & Surgeons, Danbury
New England Retina Associates, Hamden
New England Eye Center, Boston
Center for Eye Research, Boston
New England Retina Consultants, West Springfield
Delaware Valley Retina Associates, Lawrenceville
University of Melbourne, Department of Ophthalmology, East Melbourne
Marsden Eye Research Pty Ltd, Parramatta
Save Sight Institute, Sydney
Westmead Hospital, Westmead
Onci klinika FNKV, Prague
Clinique d'Ophtalmologie, Créteil
Clinique Monticelli, Marseille
Hôpital Lariboisière, Paris
Universitätsklinikum Bonn, Bonn
Universitatskliniken Koln, Cologne
Universitätsklinikum Leipzig, Leipzig
Semmelweis University, 1st Ophthalmological Department, Budapest
Lead Sponsor
Genentech, Inc.
INDUSTRY